I-Mab Gross Profit

As of the most recent data (June 2025), IMAB shows a gross profit of $0. That compares with $-1.8B in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of $66B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IMAB's gross profit is now $0 (was $-1.8B) — a 100.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether I-Mab is outperforming or lagging.

The Healthcare sector average gross profit is about $66B. I-Mab is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how IMAB stacks up against individual peers as well.

Tracking IMAB's gross profit over time shows whether I-Mab is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $-1.8B in the prior-year period — up 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has I-Mab's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $0) with ownership activity and broader fundamentals.